Jennison Associates’s ACELYRIN SLRN Stock Holding History

Jennison Associates’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-200,000	Closed	-$4.18M	–	602
2023 Q2	$4.18M	Buy	+200,000	New	+$4.09M	﹤0.01%	428

Other funds holding SLRN

ACMC

AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Jennison Associates's SLRN Position: Q3 2023 in Review

Jennison Associates sold out of ACELYRIN (SLRN) in Q3 2023, closing a stake of 200,000 shares — an estimated $4.18M sold.

Jennison Associates first reported a position in SLRN in Q2 2023 and held it in 1 quarter. The position peaked at $4.18M in Q2 2023. 101 funds tracked by Wall St. Rank hold SLRN as of Q3 2023.

Jennison Associates reported no remaining ACELYRIN position as of Q3 2023 after selling out during the quarter.
Jennison Associates sold 200,000 ACELYRIN shares in Q3 2023, an estimated $4.18M.
Jennison Associates first reported a position in ACELYRIN in Q2 2023 and held it in 1 quarter.
Jennison Associates's ACELYRIN position peaked at $4.18M in Q2 2023.
101 funds tracked by Wall St. Rank held ACELYRIN as of Q3 2023.

Based on Jennison Associates's 13F filing for Q3 2023, filed 31 Oct 2023.